Nonspecific symptoms
The anchor question: is there a unifying diagnosis behind the fatigue, pain, orthostatic intolerance, gut symptoms and brain fog, and if not, what's the honest plan? Every independent practice has these patients, and the pathway for them is still being written.
Status: Forming. Page and channel are up; the cohort needs a lead. The map below is a first draft to argue with. It gets reviewed after the February 2027 case session, where most of the outlier patients members bring will land.
Who this cohort covers
Adults with two or more years of multisystem symptoms, a normal or near-normal standard workup, and usually several prior labels: fibromyalgia, chronic fatigue, IBS, anxiety, "functional." Many have a post-infectious onset. Many overlap with the connective tissue cohort, and the two cohorts share patients on purpose.
Why a cohort and not a leftover category: objective findings turn up in a meaningful fraction of these patients when someone looks. Skin biopsy showed small-fiber polyneuropathy in 41% of a fibromyalgia cohort against 3% of controls; a small study, but a pointed one.1 POTS has consensus diagnostic criteria, a recognized post-COVID form, and treatments.2 3 And when the Undiagnosed Diseases Network ran a structured multidisciplinary evaluation on patients who had already had extensive workups, it reached a diagnosis in 35% (132 of 382), three quarters by exome or genome sequencing. A fifth of the diagnoses changed therapy; more than a third changed testing or counseling.4
The cohort isn't a claim that every such patient has a rare disease. It's a commitment to a structured search, a defined endpoint for that search, and a plan that respects the patient whether or not a label turns up.
Care map
| Role | Year 1, Establish | Year 2, Treat | Year 3, Sustain |
|---|---|---|---|
| Anchor | A timeline of the illness from the first symptom, including infections, surgeries and pregnancies. Three-generation pedigree. A structured review of systems scored once and kept. The prior labels listed and, for each, what evidence supported it. A written search plan with an endpoint. | Own the plan. One coordinating visit a quarter. Medication reconciliation with attention to polypharmacy that accumulated during the odyssey. | Annual review. Reprioritize. If the search found nothing, say so plainly, keep the door open for reanalysis, and shift the plan to function. |
| Genetics | Ask the two questions that change the pathway: is there a connective tissue phenotype (hand to the connective tissue map) and is there a family pattern. Genome sequencing when the phenotype is multisystem and objective findings exist; not as a first move for symptoms alone.4 | Interpretation of any finding with a geneticist. Cascade testing if a pathogenic variant explains the picture. | Reanalysis at 24 to 36 months if sequenced and unresolved. |
| Specialists | Autonomic or cardiology evaluation for orthostatic symptoms once hydration, salt and graded exercise have been tried for eight weeks.2 Neurology for suspected small-fiber neuropathy. Gastroenterology for motility symptoms with red flags. Allergy only when a mast cell disorder is clinically supported. | Follow positive findings only. No open-ended referral cycle; each referral has a question and a return date. | Discharge from specialists whose question was answered. |
| Diagnostics | Postural vital signs in the office, done properly (ten minutes standing). Tilt table or autonomic testing when office measurements are equivocal.2 Skin biopsy for small-fiber neuropathy when neuropathic pain or autonomic symptoms are prominent.1 Celiac serology. A metabolic and endocrine screen chosen for the phenotype, not a shotgun panel. | Repeat only what changes management. | None routine. |
| Therapies | Physical therapy with experience in dysautonomia and deconditioning: recumbent-first graded exercise, not a generic program.2 Occupational therapy for pacing and energy management. | Ongoing program with measurable targets. | Home program; periodic check-in. |
| Behavioral health and nutrition | Screen for depression, anxiety, sleep disorders and trauma without letting a positive screen end the search. Dietitian for GI symptoms and for the restrictive diets patients arrive with. | Pain psychology or CBT for symptom management, framed as part of the plan, not a replacement for it. Sleep medicine if indicated. | As needed. |
| Community | Patient organizations for the confirmed diagnosis if one is found; dysautonomia and ME/CFS organizations where they fit the picture. Set expectations about online communities. | Peer support. |
Visit one
| Ask | The illness timeline from the first symptom, with onset events. Orthostatic symptoms specifically: lightheadedness, palpitations, worse standing, better lying. Pain quality (burning, electric) and distribution. GI symptoms by type. Sleep. The family, three generations. Every prior label and who gave it. |
| Examine | Postural vital signs with ten minutes standing. Beighton score. Skin, joints, pupils, distal sensation to pinprick and temperature. Weight trajectory. |
| Order | Only what the phenotype points to. Celiac serology, thyroid, morning cortisol, B12 and ferritin if not done. Skin biopsy for small-fiber neuropathy if neuropathic features.1 Autonomic testing if office postural measurements are equivocal.2 |
| Refer | Physical therapy with dysautonomia experience now. Specialists only with a written question. Where: the procedural studies and specialist rosters. |
| Tell the patient | That the search has a structure and an endpoint; that a normal workup so far doesn't mean nothing is wrong; that function is the goal whether or not a label is found. |
| Document | The timeline, the scored review of systems, the search plan with its endpoint date, and what each prior label rested on. |
Roster for this cohort
Drawn from the procedural studies and specialist rosters: autonomic testing and tilt table, skin biopsy processing for small-fiber neuropathy, neurology with a neuropathy or autonomic interest, GI with a motility interest, and physical therapists who treat dysautonomia routinely. Forming; members propose and vet entries in the cohort's Slack channel.
Readings
- Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health expert consensus meeting, part 1. Auton Neurosci. 2021;235:102828. doi:10.1016/j.autneu.2021.102828
- Splinter K, Adams DR, Bacino CA, et al. Effect of genetic diagnosis on patients with previously undiagnosed disease. N Engl J Med. 2018;379(22):2131-2139. doi:10.1056/NEJMoa1714458
References
- Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain. 2013;154(11):2310-2316. doi:10.1016/j.pain.2013.06.001
- Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health expert consensus meeting, part 1. Auton Neurosci. 2021;235:102828. doi:10.1016/j.autneu.2021.102828
- Raj SR, Arnold AC, Barboi A, et al. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. Clin Auton Res. 2021;31(3):365-368. doi:10.1007/s10286-021-00798-2
- Splinter K, Adams DR, Bacino CA, et al. Effect of genetic diagnosis on patients with previously undiagnosed disease. N Engl J Med. 2018;379(22):2131-2139. doi:10.1056/NEJMoa1714458